increases in intensity and duration, whereas NREM progressively decreases. SWS is concentrated in the first half of the sleep period. The anatomy and duration of sleep varies across age span and health status, and the average 'normal' sleep duration is said to be 7.5 hours on weekday nights and 8.5 hours on the weekend nights. Sleep is initiated by activity in the ventrolateral pre-optic nucleus of the anterior hypothalamus, which, through inhibitory transmitters such as gammaamino butyric acid (GABA), inhibits parts of the brain that promote wakefulness. REM is generated by cholinergic neurons in the brainstem and mid brain. Neurons designated as OFF and ON neurons in the mesencephalon/pons and the locus coerulus/raphe nucleus control the switch of REM sleep. During REM sleep, there is generalised muscle atonia apart from in respiratory muscles, eye muscles and occasional muscle twitches. The functions of REM and NREM sleep continue to be debated. These include recovery, repair and consolidation of memory.
The relationship between chronic pain and sleep
Chronic non-malignant pain is often explained in terms of central pain sensitisation or hypersensitivity, a pathophysiological state which leads to allodynia (perception of pain in response to a non-painful stimulus) or hyperalgesia (increased sensitivity to pain). Nervous system regions involved in pain modulation are implicated in the generation and maintenance of sleep. Sleep shares a close relationship with pain that can be explained on the basis of bio-psycho-social factors, and this association is particularly important when it comes to chronic pain and sleep disturbance.
In the last three decades, studies on the effect of experimentally induced acute and chronic pain on sleep architecture in animals have concluded that paininduced disruption of sleep is not directly proportional to the severity of the pain. [2] [3] [4] This may help explain the lack of proportionality between the severity of chronic pain in individuals and the level of disability such as sleep disturbance that they experience as a result. 4 Experimental studies on humans show that painful stimuli disrupt sleep; 5 clinically, chronic pain is different because of the additional psychosocial components, affective disturbances and neural changes which occur in these patients. Long-term studies consistently suggest that chronic pain is a significant predictor of development of sleep problems in the future. [6] [7] [8] The relationship between chronic pain and sleep is self-reinforcing, as sleep can be affected by chronic pain, but it can also modulate the perception of pain. Animal studies have shown that REM sleep has antinociceptive properties, REM sleep deprivation reduces pain threshold and paradoxically, chronic sleep deprivation increases pain threshold (an adaptive process resulting from an increase in endorphin secretion). [9] [10] [11] Human experimental research has shown that similar tendencies with total sleep deprivation, SWS and REM sleep deprivation; that SWS recovery increases pain threshold, which is at par with analgesics such as aspirin, acetaminophen and ibuprofen; and that REM sleep is antinociceptive. [12] [13] [14] A study measuring finger withdrawal latency in human subjects found a 25% decrease in subjects with 4 hours in bed compared to subjects in a group with 8 hours in bed. 15, 16 They also used a sleep-loss protocol with interruption during either REM or NREM sleep and found a 32% decrease in finger withdrawal latency in the REM sleep-disrupted group. These results suggest that reduced total sleep time (TST) or REM sleep disruption can increase pain sensitivity in healthy individuals. Based on this, the effect of an analgesic with regard to these parameters should be considered in patient management as a modulation or disturbance may increase the perception of pain.
Sleep deprivation leading to a decrease in the ability to focus or shift attention has been shown to affect the attentional modulation of pain. 17 Sleep-deprived individuals have impaired ability to focus attention and then disengage from painful stimuli, which can lead to failure of cognitive-behavioural and distraction strategies used in pain management. 18 Changes in mood have a profound effect on the perception of chronic pain, and sleep deprivation is closely linked to depression and elevated levels of inflammatory markers, which are positively associated with increased spontaneous pain. [19] [20] [21] It is important to recognise the strength of the impact of sleep disturbance on pain, of chronic pain on sleep and the analgesic property of sleep. Therapeutic interventions aimed to treat pain would work best if the chronic pain sufferer is sleeping well. What happens when the analgesic chosen actually disrupts sleep?
Issues in chronic pain management
Chronic non-malignant pain is managed by a variety of treatment approaches spanning the entire biopsycho-social panorama. Biologically, pharmacological agents such as opioids, non-steroidal antiinflammatory drugs (NSAIDs), antidepressants and anti-epileptics have been the mainstay for decades. More recently, other agents such as cannabinoids have been increasingly used. These drugs generally act centrally through receptors and neurotransmitter systems, some of which play important roles in sleep-wake regulation. It is natural to assume that these medicines could have a significant impact on sleep-wake regulation, and considering the inter-relationship between pain and sleep, it is important that those treating chronic pain are aware of the positive and negative implications of these drugs.
Antidepressants modulate sleep parameters
Antidepressants commonly used in chronic pain conditions include tricyclic antidepressants (TCAs), serotonin and nor-adrenaline reuptake inhibitors (SNRIs), milnacipran and selective serotonin reuptake inhibitors (SSRIs). As a group, antidepressants cause measureable changes in the sleep architecture of depressed and non-depressed individuals. 22 TCAs reduce REM sleep and increase REM latency. 22, 23 This effect lasts during long-term treatment; however, there is a rebound of REM sleep when TCAs are withdrawn. 22 As a group, they also increase TST, reduce sleep onset latency (SOL) and increase SWS. Within the TCA class, amitriptyline increases SWS in both depressed and healthy individuals during long-term treatment. 22, 24 SSRIs disrupt sleep pattern by increasing wake after sleep onset (WASO) time and reducing TST, REM latency and REM sleep. 21 REM suppression may disappear with chronic treatment. 22, 25 Nor-adrenergic and selective serotonergic antidepressants may increase REM latency and rather increase REM sleep. 22 SNRIs generally reduce REM sleep, and duloxetine may increase SWS. Trazodone increases SWS and TST, with minimal effect on REM sleep.
The effect of various antidepressants on sleep architecture suggests that antidepressants can have detrimental or beneficial effects on sleep. Although antidepressants are widely used and significantly effective in chronic pain conditions, most reduce REM sleep in healthy and depressed individuals, which could indirectly increase pain sensitivity in chronic pain patients. 26, 27 A study conducted on rats explored the effects of amitriptyline on 72-and 96-hour REM sleep deprivation-induced pain sensitisation to thermal stimuli. 28 It showed no improvement in the pain threshold of the sleep-deprived groups on administering amitriptyline when compared to controls, although it confirmed an increase in pain sensitivity in the REM sleep deprivation group. This led the researchers to conclude that the mechanism resulting in hyperalgesia following REM sleep deprivation is caudal to the effects of amitriptyline in the pain modulation pathway and that sleep disruption found in chronic pain patients may hinder the analgesic effects of antidepressants. Based on this, REM sleep deprivationinduced by antidepressants should reduce their own analgesic action.
Other effects of amitriptyline on the sleep architecture include an increase in SWS and TST along with an increase in daytime sleepiness. 24 The effectiveness of amitriptyline and other TCAs in chronic pain conditions like fibromyalgia is often beyond their effects on pain and extend to their sedative properties with the effect size of TCAs on pain being the largest among most classes of antidepressants, which goes hand-inhand with their effects on sleep in fibromyalgia. 28 The improved continuity and depth of SWS by these agents could contribute to the analgesic effect in chronic pain as the partial loss or disruption of SWS is associated with increased spontaneous pain, although it is likely that the sleep improvement quality of TCAs is independent of their analgesic effects. It is possible that the analgesic effect of TCAs resulting from their effect on SWS and sleep continuity balance out any negative effects due to REM sleep suppression. Although the sedative property of antidepressants is seen as beneficial at night, residual daytime somnolence could contribute to daytime dysfunction. This can be linked to the study by Tiede et al., 17 which suggests that daytime cognitive impairment can disturb attentional modulation of pain.
Another concern related to antidepressant use is their association with sleep disorders other than insomnia, such as restless legs syndrome (RLS), periodic limb movements (PLMS) and obstructive sleep apnoea (OSA). The relationship between RLS and the use of antidepressants is controversial, with some studies reporting an increased and others reporting a negative association. [29] [30] [31] This variation in results is primarily due to the methodologies used including type of study, sample selection and type of antidepressant, not amounting to robust evidence. RLS is also associated with chronic pain conditions like neuropathy and arthritis. Patients with RLS are found to have lower pain thresholds and increased temporal summation of pain, which appears to be related to the sleep disturbance associated with RLS rather than primary painrelated psycho-physiological changes. 32 Central dopamine is thought to be involved in the pathophysiology of RLS. Antidepressants, via their effects on serotonergic and noradrenergic systems, also affect the central dopamine system, and bupropion, a dopamine reuptake inhibitor, has been shown to help with RLS. 31, 33 A recent study reports an increase in apnoeahypopnoea index in a group of insomniacs taking amitriptyline for insomnia. 34 This evidence is preliminary as the sample is small and uncontrolled, and other sleep parameters have not been considered. OSA is associated with increased pain sensitivity in people with chronic pain, and the prevalence of OSA in chronic pain patients is higher than in the non-chronic pain population. [35] [36] [37] Developing an understanding of the role of antidepressants as analgesics in chronic pain patients who have OSA becomes important after considering the increased occurrence of sleep apnoea in this population; the long-term metabolic effects of antidepressants such as TCAs, including weight gain; and the common knowledge that obesity is a strong risk factor for OSA.
Opioid-associated sleep changes may reduce their analgesic effect
Opioids act as analgesics through various opioid receptors. Centrally occurring opioids bind to these receptors to exert control over various biological systems, including pain regulation and the sleep-wake cycle. Their effect is to reduce the concentration of presynaptic algesic neurotransmitters by hyperpolarisation causing reduced synaptic transmission and inhibition of GABAergic conduction, which otherwise inhibits descending pain modulation. 38 Opioid receptors in the ascending and descending pain pathways are chiefly mu receptors, making mu the primary receptor for the analgesic effects of opioids. 38 Mu receptors also exert the respiratory depressant effect of opiates and are in proximity to brain areas regulating sleep in the descending pain pathway, that is, peri-aqueductal grey, ventro rostral medulla and nucleus raphe magnus (RVM).
Opioid therapy is known to affect sleep in different ways. Individuals on opioids report an increase in daytime somnolence, which may be related to higher doses of opioids but also give a subjective description of improved sleep quality. 39, 40 Other studies on current and former opioid addicts and healthy individuals generally report disrupted sleep. [41] [42] [43] [44] These results include reduced SWS, dose-dependent REM suppression, variable effects on TST and awakenings or arousals during sleep. Opioid use is associated with increased prevalence of central sleep apnoea (CSA), irregular breathing and reduced ability to respond to hypoxic and hypercapnoeic drives in sleep. [45] [46] [47] [48] Although most of the research on opioids and sleep-disordered breathing has focussed on CSA, the prevalence of OSA in individuals on long-term opioid therapy is also higher than the general population. An observational study on individuals with long-term methadone maintenance treatment (MMT) reports higher prevalence of OSA as compared to CSA in the same population and as compared to the general population. 49 Similarly, in a study on chronic pain patients treated with long-term opioid therapy, there was a dose-dependent higher prevalence of OSA as compared to CSA or mixed sleep apnoea for methadone but not for other opioids. 50 Research in the form of prospective studies and controlled trials studying the effect of long-term use of opioids on sleep and sleep-related breathing disorders in chronic pain patients is identified as an important gap in literature. 45 Despite the effects of opioids on sleep architecture, they are important therapeutic agents for RLS and PLMS, particularly in treatmentresistant cases. Secondary RLS is often found in chronic pain conditions such as neuropathy and arthritis where opiates can have dual benefits.
The effect of opioids on the sleep-wake cycle is thought to be controlled by opioid receptors, their indirect actions on GABAergic transmission and other neurotransmitter systems and neuromodulators such as adenosine. A relatively recent discovery in terms of the effects of opioids on pain and sleep is that of adenosine. Adenosine promotes REM sleep by increasing cholinergic tone in the pontine reticular formation through A 2A receptors and NREM sleep by acting on A 2A and A 1 receptors in basal forebrain, ventro-lateral hypothalamus and substantia innominata. In humans, it reduces allodynia and hypersensitivity to thermal and mechanical stimuli. One of the mechanisms by which opioids are said to disrupt sleep is through their effects on the availability of adenosine in these sites by acting on mu receptors (sleep disruptive) and kappa receptors (sleep promoting). 51 The latter effects are generally seen at higher doses which stimulate kappa receptors. 47 Opioid analgesics are thought to contribute to CSA through their effects on central respiratory pattern generators in the brainstem and via peripheral chemoreceptors. Their effect on the brainstem respiratory centre and on chemo-receptors is primarily due to their action on mu and delta receptors, and mu receptors, respectively. Long-term opioid use is not associated with development of tolerance to their respiratory depressant effect. However, individuals on long-term opioids develop 'ataxic breathing', an irregular waxingwaning breathing pattern that is distinct from CheyneStokes respiration of congestive heart failure. This irregular respiratory pattern is similar to that found in brain insults such as meningitis, head injury or altitude sickness. It is associated with central apnoeas and is a manifestation of long-term opioid use. This was reported in a retrospective-controlled study on 60 patients on opioids and by another study. 47, 50 Walker et al. 47 found that the risk of central respiratory events was higher in those on long-term opioids, was dosedependent, and was inversely proportional to body mass index, a finding that contrasts results from individuals not on opioids. This led them to suggest that there is a fundamental difference in how respiration is regulated in sleep in those on opioid medications as compared to the general population and that the respiratory instability in sleep in this group is due to the effect of opioids on peripheral carotid chemo-receptors that do not develop tolerance, unlike tolerance that develops for central effects such as sedation.
In addition to a higher prevalence of CSA, there is also a higher prevalence of OSA in those on opioids that is difficult to explain. The prevalence of obesity in chronic pain patients is greater, and this, rather than a direct effect of opioids, could be the reason for an increase in OSA in chronic pain patients on opioids. Walker et al. 47 propose that OSA in those on opioids can be triggered by the diminished respiratory drive which results in reduced activation of dilatory muscles of the upper airway which are unable to generate enough pressure to keep the airway open during the negative pressures of respiration. 47 Sharkey et al. 49 report a higher prevalence of OSA in MMT patients, but their sample is from a clinical trial for treatment of insomnia in MMT patients; it is an observational study, and they may have erroneously recruited a higher number of OSA individuals. The Webster et al. 50 study is also a retrospective study with no control group and a high attrition rate. These limitations reduce the clinical significance of their findings. Nevertheless, they contribute to the existing evidence base for sleep-disordered breathing in individuals on opioids.
Opioid-induced hyperalgesia (OIH) has gained interest over the last decade in the field of pain management with researchers delving into the different subtypes of OIH and mechanisms of this paradoxical physiological process where opioids, while acting as analgesic agents, also increase sensitivity to painful stimuli. 52 Various peripheral, spinal and central mechanisms have been described as possible causes of this phenomenon. Central mechanisms particularly focus on the central glutaminergic system and activation of descending pain facilitation pathways arising from the RVM. However, opioid-induced sleep interference has not yet been considered as a potential cause. At a preliminary level, an experimental study has shown that the analgesic effect of codeine is decreased in healthy individuals who are sleepy in the day as compared to those who are not. 53 Although this study points towards the variable effects of analgesics in sleepy and nonsleepy individuals, it also suggests that there may be an underlying role of opioid-induced sleep disruption, which contributes to reduced effectiveness of opioids in those with chronic pain. Alternatively, it could suggest that sleep disruption and daytime somnolence contributes to hyperalgesia, which is then seen as opioid induced. Although these are speculations with little evidence, they do present a plausible hypothesis. OIH can occur in both acute and chronic opioid treatment, and the role of sleep disturbance in OIH may be more relevant in long-term treatment. There is preclinical evidence that the central glutaminergic system is involved in sleep-wake regulation, 54 and further research to explore this potential mechanism of OIH could help in comprehending the relationship of sleep and pain in those on opioids. The involvement of the RVM ON and OFF cells in the modulation of pain in sleep and wake states studied in rats using opioid analgesics also points towards this shared mechanism. 55 
Some anti-epileptic agents positively impact sleep
Anticonvulsants are used to treat chronic painful conditions such as neuropathic pain, back pain and fibromyalgia. Those most commonly used as analgesics are carbamazepine, gabapentin and pregabalin. There is strong evidence to support the use of these medications in chronic pain. [56] [57] [58] Topiramate, levetiracetam, lamotrigine, tigabine and valproic acid are less commonly used, and evidence of their effectiveness as analgesics remains equivocal. The mechanism of action of anticonvulsants is via sodium and calcium channel inhibition, inhibition of glutaminergic transmission, facilitation of GABA or other unknown mechanisms. Similar mechanisms, such as blockade of accumulated sodium channels in neuromas and inhibition of overactive glutaminergic neurons, play a role in management of pain, particularly neuropathic, by anticonvulsants. 59 Whether these mechanisms are also responsible for their effect on sleep remains unknown.
Anticonvulsants are known to have sleep-modulating effects. In general, first-generation anticonvulsants are more sleep disruptive, being associated with a decrease in REM and SWS and increased sleep fragmentation. 60, 61 Carbamazepine is known to reduce REM sleep when given acutely. 62 In the long term, it may increase SWS but generally has minimal effects on sleep architecture. 61, 63, 64 Studies on valproate show variable effects, with some reporting an increase in stage-1 sleep (perceived as sleep disturbance) 61 and others reporting minimal effects on sleep architecture. 64 Among the newer agents, lamotrigine has been shown to have non-significant effects on sleep architecture. 63 Levetiracetam improves subjective sleep and stabilises sleep objectively by reducing WASO and improving sleep efficiency. 65 All these studies have been done either in healthy individuals or in those with epilepsy. Caution should be exercised in applying these effects to the chronic pain population.
Gabapentin and pregabalin are newer anti-epileptic agents that share some aspects of their mechanism of action. They are presumed to work via the aplha2-delta unit of voltage-gated calcium channels, binding to which reduces calcium influx that decreases the release of several excitatory neurotransmitters. 66 Gabapentin may also act by blocking neuronal synaptogenesis by binding to the aplha2-delta unit. 67 Independent of its effects on healthy individuals and epilepsy patients, pregabalin has been shown to improve pain-related sleep interference and insomnia symptoms in chronic pain populations, including those with neuropathic pain, post-stroke pain and fibromyalgia. Several studies report that pregabalin improves sleep disturbance in patients with chronic pain syndromes. [68] [69] [70] Additionally, an analysis of randomised, double-blind, placebo-controlled trials regarding the effects of pregabalin on sleep disruption showed that it significantly improved sleep outcomes in a sleep diary and in the medical outcomes study sleep scale. 71 These studies, however, have invariably looked at sleep effects by using subjective sleep measures. Objective studies done on animals have shown that pregabalin increases NREM sleep and delta power that is dose-dependent. 72 One exploratory study on individuals with epilepsy that evaluates the effect of pregabalin on sleep reports significant reduction in number of awakenings and non-significant improvement in WASO. 73 Another study on healthy adults comparing pregabalin, alprazolam and placebo reports an increase in duration and percentage of SWS, reduced awakenings, improved sleep efficiency, increased TST, modest improvement in SOL and no effect on REM sleep latency, but reduced REM duration. 74 This suggests that pregabalin has significant sleep modulatory effects that may be beneficial in chronic pain. The effects of pregabalin on pain-related sleep interference are perhaps due to its effects on pain itself, but the two effects could be independent of each other. 75 Gabapentin increases REM sleep and SWS, and reduces WASO and stage-1 sleep in both healthy adults and those with epilepsy. 63, [76] [77] [78] In studies on individuals with chronic pain, gabapentin shows reduced painrelated interference in sleep on subjective measures, 79 but there is no evidence to our knowledge of studies exploring the effect of gabapentin on sleep architecture objectively in chronic pain patients. Although the mechanisms remain unclear, a decrease in the release of excitatory neurotransmitters that contributes to arousal may be one of the possible mechanisms through which pregabalin and gabapentin improve sleep.
To our knowledge, there is no robust evidence to suggest that anticonvulsants commonly used as analgesics are associated with an increase in sleep disorders such as sleep-disordered breathing or RLS. They, however, do contribute to increased daytime somnolence, a dose-dependent side-effect that can affect pain perception in wakefulness.
Cannabinoids may have a role as opioid-sparing analgesic agents
Cannabinoids, components of marijuana and the endogenous cannabinoid system are known to play a role in analgesia, inflammation and sleep. Several reviews discuss the role of endogenous cannabinoids, particularly that of CB1 and CB2 receptors in peripheral, spinal and supra-spinal pain modulation. 80, 81 The supra-spinal regions of the brain implicated in cannabinoid-induced central analgesia in physiological conditions include the thalamus, peri-aqueductal grey, RVM and amygdala. 80, 81 Clinical studies in patients with chronic pain report modest effect of cannabinoids as therapeutic agents for chronic non-malignant pain in short-term use. 82, 83 Although these systematic reviews report an improvement in pain with cannabinoids, the quality of the evidence is humble because of the quality of trials included in the reviews, that is, short-term studies, small sample sizes and unclear clinical outcomes, making them less than optimal trials. In addition, cannabinoids are also laced with increased incidence of adverse effects as suggested by a later review. 83 Long-term studies on the effects of cannabinoids on pain are scarce.
The role of cannabinoids in the sleep-wake cycle was first identified by experiments four decades ago. [84] [85] [86] The place of endocannabinoids in the sleep-wake cycle has been described in recent reviews. 87, 88 The endocannabinoid, anadamide is described as sleep promoting primarily through its action on the CB1 receptors. This may involve the stimulation of adenosine and acetylcholine release through activation of cholinergic neurons in the basal forebrain and brainstem (sites of CB 1 receptors) by endogenous anadamide or exogenous cannabinoids, which then promote sleep through their projections to the thalamus and resultant cortical de-synchronisation. 87 Short-term administration of delta-9-tetrahydrocannabinol (THC) reduces REM sleep and increases SWS, whereas longer administration of THC reduces SWS in humans and animals. 85, 88 Administration of THC doses in the higher amount has been shown to have sleep-promoting effects over a short period of time; 89 however, long-term effects are not clearly known, particularly because of some evidence that long-term administration of THC actually reduces SWS. The non-psychoactive cannabinoid called cannabidiol is described as a wake promoting agent in contrast to THC. 90, 91 This suggests that cannabinoids have a complex effect on the sleep-wake cycle and different preparations have varying effects ranging from sleep promotion to alertness and reduced somnolence.
As the primary central receptor of cannabinoids is the CB1 receptor, it can be suggested that this receptor is the main mode of the shared action of cannabinoids on sleep and pain. Studies on the effects of cannabis and synthetic or plant-derived cannabinoids (e.g. nabilone) report improvement in sleep and pain as primary or secondary outcomes in patients with chronic pain conditions such as fibromyalgia, neuropathic pain and multiple sclerosis. 89, 92, 93 The improvements reported vary from high to no improvement. No studies to our knowledge have been done which measure change in pain along with objective measurement of sleep.
Cannabinoid agents may have an opioid-sparing effect when used in conjunction with opioids for management of chronic pain conditions, particularly in palliative care. 94 This suggestion is based on preclinical studies on rodents and experimental studies on humans. Limited studies have looked at the synergistic use of opioids and cannabinoids in the clinical situation. Roberts et al. 95 examined the synergistic effect of THC and morphine in experimentally induced thermal pain in healthy volunteers. They reported a statistically significant improvement in the affective component of pain but not the sensory component of pain with the combined use of morphine and THC. The effect of either THC or morphine alone was negligible. The researchers suggested that the change in affective aspect of pain was an indication that this combination may be more effective in chronic pain where the affective component is equally important. They also stated that the lack of efficacy of THC suggested that THC may not be an effective analgesic. But the dose and mode of administration of THC in this study may have contributed to the lack of an effective analgesic effect. The oral mode of THC administration is less effective as an analgesic and administration of higher doses of THC are required for adequate analgesia and sleep promotion. 89 The primary purpose of discussing the synergistic effect of opioids and cannabinoids for pain is to focus on the effect cannabinoids may have on sleep when used together with opioids in chronic pain conditions. Carley et al., 96 in a unique study on rats, reported that cannabinoids, that is, THC and oleamide, significantly reduced rates of apnoea in REM and NREM sleep and blocked serotonin induced increase in sleep apnoea in these rodents. This led them to propose that cannabinoids may have an important role to play in maintaining autonomic stability during sleep and in reducing sleep apnoea in human beings as well. Dempsy 97 argued that though this was an encouraging discovery with clues concerning the possibility of finding pharmacological agents to treat sleep apnoea, the complexity, function and impact of sleep apnoea, which are often mixed and obstructive in humans as compared to the primarily central apnoea in rodents, made it less likely for the results of this study to be replicable in humans. Perplexingly, no other studies have pursued this finding. The beneficial effect of cannabinoids on reducing CSA in rodents in the Carley et al. 96 study hints towards researching the use of cannabinoids as adjuvant therapy with opioids in chronic pain, considering that opioids provoke central apnoea in humans. This could potentially have multiple beneficial effects, including acting synergistically with opioids in reducing pain, improving sleep, having an opioid-sparing effect and reducing central apnoeas.
Withdrawal from long-term cannabis use is associated with worsening of sleep parameters, which has been objectively reported as a reduction in TST, sleep efficiency, REM latency and REM and an increase in SOL, WASO and PLMS. 98, 99 The withdrawal effects on sleep persist for several weeks, and the increased rate of PLMS may persist for a longer duration. 98 These studies are limited in their meticulousness in excluding previous sleep disturbance but nevertheless report effects of withdrawal from cannabis, which, although not completely transferable to withdrawal from medicinal cannabinoids, gives some evidence toward the possibility of worsening sleep and resultant effect on pain when changing or withdrawing a patient from these agents. Opioid and cannabis-dependent individuals have more pronounced sleep disturbance on withdrawal from cannabinoids as compared to individuals who are only cannabis dependent. 100 This is of clinical importance in situations where a patient is on combination cannabinoid and opioid treatment for pain.
Use of cannabinoids in any situation increases somnolence, which, though helpful at night, is often cited as problematic in the day. Daytime somnolence is associated with impaired cognitive performance and is often a reason for terminating treatment with cannabinoids. Reduced effectiveness of analgesics and impaired attentional modulation of pain in individuals with daytime impairment and somnolence is of relevance here. Other side-effects of cannabinoids, such as psychiatric symptoms, cognitive impairment and other neurological symptoms, may further complicate the use of cannabinoids in chronic pain where the patient is already experiencing a plethora of similar symptoms.
Non-steroidal anti-inflammatory agents tend to be sleep neutral or sleep promoting
NSAIDs are among the most commonly used analgesics. NSAIDs act by inhibiting cyclo-oxygenase 1 and cyclo-oxygenase 2, enzymes which are important for the production of prostaglandins. Prostaglandins play a role in sleep regulation in the central nervous system. Hayaishi 101 has described the role of prostaglandins D2 and E2 in regulation of sleep and wakefulness and proposed that adenosine is involved in the sleeppromoting effects of prostaglandin D2. Prostaglandin D2 stimulates the production of adenosine, and adenosine via its action on A2A receptors inhibits wakefulness and induces sleep. Prostaglandin D2 is most abundant in areas of the human brain which are involved in the regulation of sleep (i.e. pre-optic hypothalamus and pineal gland), and prostaglandin E2 is most abundant in the human brain in the anterior hypothalamus which is involved in temperature regulation. 102 Hence, it can be supposed that NSAIDs may influence sleep by affecting the levels of prostaglandins.
Murphy et al. 102 reported that both ibuprofen and aspirin, unlike acetaminophen, reduced sleep efficiency and increased percentage and frequency of WASO. The sleep efficiencies reported were 87.5% ± 2.1% for ibuprofen and 91.0% ± 2.4% for aspirin, a statistically significant drop from 96.2% ± 0.6% for the placebo-controlled group. All three drugs increased the percentage and frequency of WASO; however, the only drug reported to increase awakenings and stage wake percentage to a statistically significant amount was aspirin, which measured 20.0% ± 3.2% and 9.0% ± 2.4%, respectively. Ibuprofen had a statistically significant increase only for stage wake percentage, measuring 12.5% ± 2.1%. This is contrasted with 10.0% ± 2.3% awakenings and 3.8% ± 0.6% stage wake percentage for the placebo-controlled group. They also found that ibuprofen delayed SWS latency. The conclusions of the study were that NSAIDs have detrimental effects on sleep in healthy individuals and proposed that the effect on prostaglandin D2 is reduced melatonin secretion and modification of body temperature as the possible underlying mechanisms. The latter suggestions were on the basis of previous studies which have reported a potent suppression of melatonin release by NSAIDs given prior to bedtime and on the role of prostaglandin E2 as a pyrogen. [102] [103] [104] This is in contrast to the findings in a recent, well-conducted industrysponsored trial with a smaller sample of 30 healthy individuals. 105 Here, three nights of polysomnography (as compared to two nights in the previous study) did not report any statistically significant differences between those taking placebo and ibuprofen. Another controlled study on the effect of tenoxicam on rheumatoid arthritis patients reported improvement in pain but no changes in sleep parameters over 90 days of treatment. 106 To further complicate this issue, another trial on women with dysmenorrhoea treated with therapeutic doses of diclofenac has reported subjective and objective improvement in sleep, including sleep quality, sleep efficiency, REM sleep and a reduction of stage-1 sleep. 107 In the Murphy et al. 102 study, there was no change in sleep quality. In the other studies quoted above, which include healthy individuals and chronic pain individuals, there is a report of either improved or no change in sleep quality. Apart from one case report that suggests that indomethacin can exacerbate OSA, no additional evidence suggests that sleep disorders are precipitated or aggravated by NSAIDs. 108 
Conclusion
An understanding of how analgesics modulate sleep can help health-care providers in choosing appropriate agents for chronic pain patients where multiple comorbidities exist. An understanding of the bidirectional relationship of pain and sleep with respect to antidepressants will help choose appropriate antidepressants for pain relief in chronic pain patients where multiple co-morbidities exist. For example, an antidepressant that causes weight gain in an individual who is struggling with pain might contribute to sleep-disordered breathing. This can have a counterproductive effects on pain control with further weight gain, requirement of higher doses of analgesics and sleep disruption as a result of sleep-disordered breathing.
In the case of opioid analgesics, despite the subjective improvement in sleep reported by patients on low doses of opioids, it appears that when it comes to the overall effect of opioids on sleep physiology, the scale tilts towards the counterproductive side. These sleep-disruptive effects worsen the overall quality of sleep, which in turn affects pain management and effectiveness of opioids as analgesics. This should not be interpreted as a disadvantage. It rather emphasises the importance of choosing the right agent and encourages the option of using opioid-sparing agents that preclude the use of high doses of opioids. It also hints towards the underlying reasons of why opioids are sometimes not optimally effective in treating pain and how underlying sleep disturbance may contribute to this.
Considering anticonvulsants, there is enough evidence to support their use in chronic pain, particularly neuropathic pain, and evidence is gathering that some also positively impact the sleep architecture. Most evidence for a synergistic effect on sleep and pain is available from pregabalin and gabapentin. Although the underlying physiological mechanisms remain to be understood, the general view that develops from this is that the newer anti-epileptics improve sleep in addition to pain. This does not necessarily translate into a recommendation for newer anticonvulsants such as gabapentin and pregabalin as superior for mutual sleep and pain improvement because their favourable effects on sleep parameters are modest in effect size. In addition, both gabapentin and pregabalin have the sideeffect of clinically significant daytime somnolence, and pregabalin is associated with weight gain. These adverse effects can compromise the effectiveness of anticonvulsants as analgesics particularly because daytime sleepiness is associated with reduced analgesic effects 67 and weight gain is a strong risk factor for sleep apnoea.
Clinical experience suggests and the Food and Drug Administration recommends that both pregabalin and gabapentin should be tapered slowly because abrupt discontinuation may result in sleep disturbance among other problems, particularly falling and staying asleep. No studies have looked into this phenomenon meticulously. Despite this, due to their relative sleep-promoting or sleep-sparing actions, they are probably better alternatives in patients who already are at risk of developing sleep disorders.
Although there is an increasing amount of research being done on the cannabinoid system, science remains in its infancy of understanding the synergistic role of cannabinoids in sleep and pain. Their use in clinical practice is limited to selected approved use in nausea during chemotherapy in cancer patients (the United States and Canada) and multiple sclerosis (Canada and the United Kingdom) and off-label use in chronic pain and insomnia. Studies evaluating the effect of cannabinoids on objectively measured sleep in chronic pain patients, the neurophysiology of their interaction with other analgesics, their use in sleep disorders such as sleep apnoea and their analgesic sparing effects are required to better understand the role of these agents in co-management of pain and sleep. Although cannabinoids are not first-line analgesics, their combination with other analgesics as adjuvant therapy can be clinically useful. Nevertheless, this decision should be carefully reached after weighing the risks and benefits by considering their effects on the individual's sleep and daytime functioning.
The discussion on NSAIDs leads to a tentative conclusion that they are at least neutral if not sleep promoting in chronic pain primarily because of their analgesic effects, despite having a theoretically negative impact on sleep-wake regulation. This is after consideration that the effects of one or two nights of NSAIDs on sleep in healthy individuals cannot be translated into the effects of long-term NSAID use in chronic pain patients where there is a complex interplay between several bio-psycho-social factors influencing sleep and pain. This conclusion, however, is cautious and leaves plenty of room for further research into the effects of NSAIDs on sleep in chronic pain particularly in long-term use.
Important clinical practice points that can be summarised include the following:
1. Pharmacological agents commonly used to treat pain have significant beneficial and detrimental effects on the sleep-wake cycle that should be considered when prescribing analgesics. 2. NSAIDS are least disruptive on sleep, and the use of opioids is associated with significant negative effects on sleep.
3. Anti-epileptics such as pregabalin and gabapentin may have a beneficial effect on sleep but the evidence for this is preliminary. 4. In circumstances where pain is not effectively controlled with analgesics, one solution is to explore the patient's sleep.
Research recommendations that can be extracted from the above summary include the need for focussed research to clearly understand how sleep disruption due to analgesics impacts on their effectiveness in pain relief, and to explore the effect of opioids and antidepressants on sleep stages and sleep disorders in humans. On the other hand, research on the analgesic effect of non-pharmacological approaches in managing insomnia and other sleep disorders is gaining momentum and leaves avenues open for further research into improving pain management non-pharmacologically.
